Pfizer Stops Work on Danuglipron: A Problem for Obesity Treatment Studies.

Pfizer will stop working on its once-a-day pill for obesity. This is because a person in a test had a liver problem that might be from the drug. The person got better after they stopped taking the pill.

The pill was being tested to find the right amount to give people. Pfizer wanted to do bigger tests later, but now they will not. An official said that Pfizer will still work on other obesity treatments that are not as far along.

Obesity treatments are making a lot of money for drug companies. Eli Lilly's Zepbound made almost $5 billion in its first year. The most popular drugs now are shots, but companies want to make a pill that is easier to take.

Lilly is waiting for test results on some pills they made. It can be hard to get these drugs because of shortages or insurance problems. Lilly and Novo have lowered prices, but they are still expensive for some people.

Pfizer stopped working on a pill that people took twice a day last year. Too many people in the test stopped taking it. The company will also stop testing the drug with other drugs for obesity.